Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma

BACKGROUND: Glycogen synthase kinase (GSK)-3β has emerged as an appealing therapeutic target for glioblastoma (GBM). Here, we investigated the therapeutic effect of the current approved drugs against GBM via inhibition of GSK3β activity both, in experimental setting and in a clinical study for recur...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Furuta, Takuya, Sabit, Hemragul, Dong, Yu, Miyashita, Katsuyoshi, Kinoshita, Masashi, Uchiyama, Naoyuki, Hayashi, Yasuhiko, Hayashi, Yutaka, Minamoto, Toshinari, Nakada, Mitsutoshi
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2017
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5410264/
https://ncbi.nlm.nih.gov/pubmed/28423558
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15206
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items